Approximately 40–50% of GBMs carry EGFR amplifications; among EGFR-amplified GBMs, in 20–50% of cases, a splice variant which creates a mutant form of EGFR (EGFR vIII) is present, conferring a more aggressive tumor biology [12,13]. Here, EGFR is linked to neoplasm.